ArticleInternational journal of nanomedicine2026
Selenium-Doped Calcium Hydroxide Nanoparticles Inhibit Osteoclasts and Promote Osteogenesis for Osteoporosis Treatment.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Osteoporosis is characterized by an acidic and oxidative stress microenvironment driven by excessive osteoclast activity, which impairs osteogenesis and leads to dysregulated bone remodeling. This study aims to develop selenium-doped calcium hydroxide nanoparticles (SeCaNP) to simultaneously inhibit osteoclastogenesis and promote osteogenic differentiation, thereby providing a multi-targeted microenvironment-modulating strategy for osteoporosis therapy. Methods: SeCaNP was synthesized via a coprecipitation method and characterized using TEM, XRD, and acid-neutralization assays. In vitro, bone marrow-derived macrophages (BMMs) and bone marrow mesenchymal stem cells (BMSCs) were co-cultured with SeCaNP to assess osteoclast activity and osteogenic differentiation. In vivo, an ovariectomy (OVX)-induced osteoporosis mouse model was established and treated with local injections of SeCaNP. Therapeutic efficacy and biosafety were systematically evaluated. Results: SeCaNP significantly upregulated GPx1 expression, effectively scavenged reactive oxygen species (ROS), and neutralized the intracellular acidic microenvironment, thereby markedly inhibiting osteoclastogenesis. Concurrently, SeCaNP promoted BMSC cytoskeletal remodeling and significantly enhanced osteogenic differentiation and mineralization, upregulating key markers (RUNX2, ALP, OPN, OCN). RNA-seq analysis indicated that SeCaNP regulated osteogenesis-related membrane signaling platforms and extracellular matrix assembly. In vivo, SeCaNP treatment significantly ameliorated OVX-induced bone loss, notably improving bone mineral density (BMD) and trabecular microarchitecture parameters (BV/TV, Tb.N, Tb.Th). Furthermore, SeCaNP upregulated BMP-2 expression and serum BALP levels without inducing systemic toxicity. Conclusion: SeCaNP effectively overcomes the limitations of conventional osteoporosis therapies by integrating acid neutralization, antioxidant properties, and osteogenic support. Through a dual-regulatory mechanism that inhibits bone resorption and promotes bone formation, SeCaNP successfully reconstructs the pathological bone microenvironment and reverses bone loss, highlighting its significant potential as a microenvironment-modulating biomaterial for anti-osteoporotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.